• Tumors reroute niacinamide away from energy production — To understand why this matters, think of NAD+, the molecule your cells rely on to produce energy, as your cells' master battery charger — present in every cell in your body and essential for hundreds of metabolic reactions. When something diverts the raw material needed to make it, cellular energy production suffers across the board.

In laboratory models (multiple glioblastoma cell lines) and human tumor samples, scientists found a dramatic shift: niacinamide stopped feeding into NAD+ and instead got converted into a different compound called N1-methylnicotinamide.*

In simple terms, the tumor diverts a key fuel source away from energy production and into a side pathway. In human patients, the study reported about a sevenfold higher buildup of this compound in tumor tissue compared to surrounding healthy brain. That suggests the tumor may be actively rewiring how it uses nutrients to survive.

• This metabolic detour becomes even more pronounced in real patients — When researchers gave labeled niacinamide to patients before surgery, they tracked exactly where it went. Inside tumor tissue, about 40% of that niacinamide ended up as N1-methylnicotinamide, while a smaller portion supported NAD+ production. That imbalance shows the tumor strongly favors this altered pathway.

This reveals a key insight: cancer cells fundamentally change how they handle nutrients you consume.

• Steroid treatment amplifies the problem inside tumors — Dexamethasone, the steroid routinely given to reduce brain swelling and keep patients comfortable, appears to accelerate the very metabolic process that helps the tumor survive. It does this by increasing the activity of an enzyme called NNMT, which acts like a switch that pushes niacinamide down the pathway the tumor has hijacked rather than toward energy production.

The study showed that steroid exposure consistently raised both the enzyme levels and the buildup of the altered metabolite in tumor cells. This effect appeared across different tumor models, showing it's not a rare event. That means a common treatment you might assume is harmless in terms of metabolism actually reshapes how cancer cells operate at a deep level.

• Tumors accumulate far more of this compound than normal brain tissue — In studies involving animal models, levels of N1-methylnicotinamide were about 10 times higher in tumors than in healthy brain tissue. Even more striking, steroid treatment boosted this compound by 85% in tumors but not in normal brain.*

That selectivity tells you something important: the tumor environment reacts very differently to the same signal. This difference opens the door to targeting cancer without affecting healthy tissue in the same way.

• The process drains key cellular resources — Converting niacinamide into N1-methylnicotinamide consumes methyl groups; think of these as your body's universal keys, needed to switch genes on and off, neutralize toxins, and keep cells replicating properly. When the tumor burns through them to run this pathway, it's depleting a resource every cell in your body depends on.

The study showed a drop in a ratio that reflects the cell's ability to carry out these reactions. When this ratio falls, the cell's internal balance gets disrupted. This means the tumor is burning through resources in a way that weakens its own system under the right conditions.

• Scientists identified a new way to detect tumors using this pathway — Because tumors produce so much of this altered compound, researchers developed an imaging approach using labeled niacinamide to visualize tumors in real time. This gives clinicians a clearer way to see where tumors are active based on metabolism, not just structure. That shifts diagnosis from "what it looks like" to "how it behaves," which gives a more precise picture.

• This research reframes cancer as a metabolic problem you can influence — By showing that glioblastoma cells actively divert a key nutrient away from energy production, the study highlights a core weakness in cancer metabolism. When you think about your own health, this reinforces a powerful concept: how your body processes nutrients influences disease at a cellular level.

Understanding that gives you a clearer path to take control, step by step, by focusing on the systems that drive cellular energy rather than just the symptoms you see on the surface.

• Excess niacinamide acts like a metabolic "drain" that weakens tumor fuel systems — In a related commentary, bioenergetic researcher Georgi Dinkov explains that when niacinamide levels rise, they saturate the enzyme responsible for making NAD+ and get redirected into another pathway that consumes methyl groups from methionine.³

Think of it this way: the tumor is running a metabolic process that backfires on itself. To handle all that niacinamide, it has to spend methyl groups — the same chemical currency it needs for dozens of other essential functions. Flood the system with niacinamide and you're essentially forcing the tumor to spend faster than it can earn, draining its own reserves.

That's the methyl sink. Framed this way, the same process observed in the study becomes a target; increasing niacinamide intake may help pressure the tumor's fuel system by draining some of the inputs it needs to grow.

• This mechanism mimics methionine restriction, which has been associated with reduced tumor metabolism in research — Dinkov's commentary highlights that excess niacinamide effectively forces the body into a state similar to methionine restriction, a strategy that has shown promise in slowing cancer growth in research and improving metabolic health. By consuming methionine through this pathway, tumor cells lose access to a key amino acid that acts as a metabolic regulator.

This reinforces what the study demonstrated when methionine restriction reduced tumor growth, but translates it into a practical insight: shifting how your body uses nutrients can recreate the same metabolic pressure on cancer cells without relying only on dietary restriction.

You may wonder whether this means you should also restrict methionine in your diet — a question the research raises but doesn't fully resolve. Low-methionine diets have been studied in cancer contexts and show promise, but the more practical takeaway here is that niacinamide may create similar metabolic pressure without requiring strict dietary restriction.

• Patients with newly diagnosed glioblastoma showed improved disease control — The study included adults between 18 and 75 years old who were newly diagnosed and eligible for standard treatment. Researchers found that adding niacin was associated with improvement in short-term outcomes.

Specifically, 82.3% of patients showed no disease progression at six months, compared to the typical rate of about 53.9% seen with standard care alone.⁵ That's a 28% absolute improvement, which stands out in a disease where progress has remained stagnant for decades.

Put simply: with standard care, roughly half of patients see their tumor progress within six months. With the addition of high-dose niacin, that dropped dramatically; more than four out of five patients held stable through that same window. In a disease where every stable month matters, that's a meaningful shift.

• Most patients maintained stability during a key early window — The six-month mark matters because glioblastoma often progresses rapidly after treatment begins. In this study, the majority of patients held stable through that window. This suggests niacin may have helped delay tumor progression during one of the most vulnerable phases of the disease. This translates into more time with controlled disease and fewer immediate setbacks.

Patients in this study received niacin at the start of standard therapy rather than later in disease progression. That timing aligns with the observed improvements in early disease control. It suggests that influencing metabolism and immune activity upfront may create a stronger impact than waiting until the tumor advances further.

• Higher doses reached a defined threshold for safety and effectiveness — Researchers gradually increased niacin doses from 500 milligrams (mg) up to 3,000 mg per day to identify the optimal range. They determined that 2,000 mg daily provided the best balance between effectiveness and tolerability. Side effects were mostly mild, with flushing being the most common.

• Niacin restored immune cell function that tumors suppress — The study reported that niacin improved the activity of immune cells responsible for attacking cancer. Glioblastoma weakens these cells, reducing their ability to respond. Niacin appeared to reverse that suppression, allowing immune cells to recognize and target tumor cells more effectively.

Study author Wee Yong, Ph.D., explained, "Niacin treatment rejuvenates immune cells so they can do what they are supposed to do: attack and kill the cancer cells."⁶ The tumor had shut down the immune response, and niacin helped switch it back on.

• The findings highlight a combined metabolic and immune strategy — By improving both disease control and immune activity, the study points to a dual-action effect. Instead of targeting the tumor from a single angle, niacin supports internal systems that influence how the tumor grows and how your body responds. This reinforces a key takeaway: changing how your body processes nutrients and supports immune function may influence the trajectory of the disease.

1. Restore steady cellular energy with adequate carbohydrates — Cells rely on consistent fuel to maintain efficient energy production. Daily carbohydrate intake of about 250 grams supports mitochondrial function and may help reduce exposure to stress-driven pathways.

If digestion feels compromised, starting with whole fruit and white rice helps ease the transition before adding more complex carbohydrates. This step supports general mitochondrial health rather than directly targeting the niacinamide pathway, but stable cellular energy production is the foundation everything else builds on.

2. Strengthen immune response with nutrient-dense vitamin B3 sources — The study showed that niacin improved immune cell function that tumors had suppressed. Regular intake of whole-food sources of vitamin B3 such as grass fed beef supports both energy production and immune readiness.

Consistency matters because immune cells require steady nutrient availability to stay active and responsive. Grass fed beef liver is particularly worth including; it contains dramatically more niacin per serving than muscle meat and also provides other B vitamins that support the same energy pathways discussed in the research.

3. Eliminate seed oils to reduce metabolic and immune disruption — Excess linoleic acid (LA) from vegetable oils like soybean, corn, sunflower, and canola interferes with mitochondrial function and increases inflammatory stress. Removing these oils and replacing them with stable fats such as grass fed butter, ghee, or tallow reduces one of the major drivers of cellular dysfunction. This change supports both energy production and immune signaling.

4. Optimize protein intake to support repair and immune resilience — Protein intake around 0.8 grams per pound (or 1.76 grams per kilogram) of lean body mass supports tissue repair, enzyme production, and immune cell function. Including roughly one-third from collagen-rich sources like slow-cooked meats or bone broth helps maintain structural and metabolic balance without overwhelming the system.

5. Use structured niacinamide intake to reinforce energy metabolism — Small, evenly spaced doses support steady NAD+ production instead of overwhelming your system at once. A practical approach involves about 50 mg of niacinamide taken three times per day, spaced evenly — upon waking, midday, and before bed.

This is niacinamide, the non-flushing form of vitamin B3, used here to support NAD+ production and mitochondrial energy metabolism as a general health practice. This is distinct from the high-dose niacin used in the clinical trial, which was medically supervised and targeted immune activation at doses up to 2,000 mg daily. Do not attempt to replicate the clinical protocol without physician oversight.